One-Day brain zaps: a new hope for stubborn depression?
NCT ID NCT07758010
First seen Aug 11, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This trial tests whether a single day of accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Participants are randomly assigned to receive one of two active TMS protocols—targeting the precuneus or the left dorsolateral prefrontal cortex—or a sham (inactive) treatment. The study compares changes in depression scores over four weeks to see if either active approach outperforms the placebo-like sham.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial magnetic stimulation (TMS) targeting the precuneus or the left dorsolateral prefrontal cortex
- What this could lead to
- If it works, this could offer a fast, non-invasive option for people with treatment-resistant depression, potentially easing symptoms within weeks.
- What could go wrong
- This is an early-stage trial, and the effects may be modest or not last. TMS can cause scalp discomfort or headache, and not everyone responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 69 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older. * Able to speak, read, and understand English sufficiently to complete the study assessments and provide informed consent independently. * Diagnosis of major depressive disorder according to DSM-5-TR criteria, confirmed by a qualified physician. * Treatment-resistant depression, defined as an inadequate response to at least two adequate trials of antidepressant pharmacotherapy. * Patient Health Questionnaire-9 (PHQ-9) total score of 10 or higher. Exclusion Criteria: * Any condition identified through TMS safety screening that, in the judgment of a study physician, presents an unacceptable safety risk for TMS. Such conditions may include: * A history of a serious adverse reaction during TMS treatment. * A history of seizure. * A history of stroke. * A history of serious head injury or neurosurgery. * Metal in the head outside the mouth, such as shrapnel, surgical clips, or metal fragments. * An implanted device, such as a cardiac pacemaker, cochlear implant, medical pump, or intracardiac line. * Frequent or severe headaches. * Another brain-related condition or an illness that caused brain injury. * A family history of epilepsy. * Permanent tattoos on the head or neck. * Current recreational drug use. * Current pregnancy or possible pregnancy. * Use of a medication or combination of medications, a recent medication change, or medication withdrawal that, in the judgment of a study physician, presents an unacceptable safety risk, including a clinically significant increase in seizure risk. * Current or lifetime diagnosis of bipolar I disorder, bipolar II disorder, a schizophrenia spectrum disorder, or another primary psychotic disorder. * Active suicidal ideation with intent or plan requiring immediate clinical intervention, or another acute safety concern that cannot be safely managed within the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depressive disorder, treatment-resistant are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
McLean Hospital
RECRUITINGBelmont, Massachusetts, 02478, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does the setting shape Ketamine's effect on depression?
- Can a Brain-Signaling drug crack depression that resists standard treatment?
- Can Anti-Inflammatory drugs lift depression that Won't budge?
- Can magnetic brain stimulation keep depression at bay longer than a drug?
- Can the immune system hold the key to treating resistant mental illness?
- Could group talk boost the benefits of psychedelic therapy for depression?